Reduction in expression levels of glutathione Stransferase (GST) l type 1 (GSTM1) in stroke-prone spontaneously hypertensive rats has recently been reported. GSTM1 genotype was evaluated in 49 patients with resistant hypertension and compared with selected patients with controlled hypertension (n ¼ 232) and healthy participants (n ¼ 110). Null GSTM1 genotype occurred more frequent in patients with resistant hypertension than those with controlled hypertension (57.1 vs 39.7%; P ¼ 0.03; RR 1.96; 95% CI 1.04-3.69) suggesting that null GSTM1 genotype may predispose to resistant hypertension.
Genetic determinants of human hypertension are poorly understood although polymorphisms in several genes have been associated with elevated blood pressure levels.
Hypertension is termed resistant when a therapeutic approach including lifestyle modification fails to attain pre-defined blood pressure levels.
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Prevalence of 'true' resistant hypertension (excluding secondary causes of hypertension, white coat hypertension, inadequate doses and so on) is about 5% in the general hypertensive population. 3 A few studies have evaluated genetic determinants of refractory hypertension [4] [5] [6] but others suggest that it occurs as a result of poor treatment adherence or suboptimal therapy. 1 It has been recently observed that stroke-prone spontaneously hypertensive rats had significantly reduced levels of glutathione S-transferase (GST) (m type 1) M1 expression. 7 Lower glutathione Stransferase m type 1 (GSTM1) expression levels were associated with increased superoxide levels and reduced nitric oxide bioavailability in the rat renal medulla and cortex. 7 It has been suggested but not shown that human participants who have a GSTM1 null genotype may be prone to atherosclerosis and endothelial dysfunction and subsequent development of hypertension. 7 We therefore hypothesized that variations in human GSTM1 may determine susceptibility to hypertension and resistant primary hypertension.
Controlled hypertension was defined as a systolic/diastolic blood pressure of o140/90 mm Hg (o130/80 mm Hg in diabetics) on three separate occasions after treatment. Patients were considered to have resistant hypertension when a therapeutic plan that included lifestyle modification (including smoking cessation and achieving a body mass index at least o30 kg m À2 ) and prescription of at least three drugs, including an adequately dosed diuretic, failed to achieve the target blood pressure of o140/ 90 mm Hg (o130/80 in diabetics) on any occasion during follow-up. The most common causes of secondary hypertension were excluded in these patients.
Patients were seated quietly for at least 5 min and blood pressure measurements were performed at least twice using a Hawksley random zero mercury sphygmomanometer with an appropriate cuff size, and verified three times with an Omron Automatic Blood Pressure Monitor, Model HEM-773AC (Omron HealthCare Inc., Bannockburn, IL, USA), the mean value of the manual measures were used for the analysis. Ambulatory blood pressure monitoring (24 h) was measured using an Oscar ambulatory blood pressure monitoring system (SunTech Medical Inc., Morrisville, NC, USA) and performed at least twice in patients with resistant hypertension during follow-up. Target organ damage was assessed by both echocardiograph and fundoscopy. Degree of left ventricular hypertrophy and retinopathy were determined. Significant retinopathy was defined as grade X2 and left ventricular hypertrophy as left ventricular mass 4125 g m À2 in men or 110 g m À2 in women. Treatment adherence was confirmed in all the patients by analytic control and adherence tests.
Consecutive patients attending the Hypertension Unit of the University Hospital of Salamanca were screened prospectively over a period of 42 months and those with resistant primary hypertension were identified. Selected age and sex-matched controlled hypertensive patients were identified (n ¼ 236) and healthy controls (n ¼ 112) were included for comparison.
Patients were treated according to the recommendations of the current guidelines for management of arterial hypertension with full doses.
1,2 The study was approved by the local Ethics Committee and all the participants gave informed written consent before inclusion.
Analysis of the GSTM1 gene was performed by PCR (primers GSTM1: 5 0 -CGC CAT CTT GTG CTA CAT TGC CCG -3 0 ; 2: 5 0 -ATC TTC TCC TCT GTC TC-3 0 and 3: 5 0 -TTC TGG ATT GTA GCA GAT CA-3 0 ) that amplify exons 4 and 5. Primers 1 and 2 amplify GSTM1 as well as the GSTM4 gene. Primer 3 is specific for GSTM1. 8 Normally distributed parametric data are expressed as mean ± s.d. and compared using Student's t-test or ANOVA (analysis of variance) test. Chi-square test was used for comparison of categorical variables. Logistic regression, including age and sex as confounding factors, was applied to evaluate differences in allele frequencies between participants. A P-value o0.05 was regarded as significant. All statistical analysis was performed using Statistical Package for Social Science (SPSS) version 14.0.
All participants were Caucasian. Among the screened cohort attending the hypertension clinic (n ¼ 950), 49 participants with resistant hypertension were identified. Patients with resistant hypertension were women in 64% of cases and of mean age 68±11 years. They did not differ significantly, in terms of demographic characteristics, from the controlled hypertension cohort and the healthy controls. Resistant hypertension patients were treated with a mean of 3.7 antihypertensive drugs (100 diuretics, 50 angiotensin converting enzyme inhibitors, 68 angiotensin II receptor antagonists, 70 b-blockers, 24 a-blockers, 58 calcium channels blockers and 2% others). Treatment did not differ significantly in number and type of drug from that in the controlled hypertension group.
Mean values of systolic and diastolic blood pressure for those with resistant and controlled hypertension were 164/95±15/9 mm Hg and 132/ 83 ± 10/7 mm Hg, respectively. A higher prevalence of retinopathy and left ventricular hypertrophy was detected in those with resistant rather than controlled hypertension (80 vs 53% Po0.02 for retinopathy; 75.8 vs 44.1% Po0.001 for left ventricular hypertrophy) and longer history of hypertension was detected in the resistant group (17.05±12 vs 8.61 ± 8 years from the diagnosis of hypertension; Po0.001). However, these comparisons were not controlled by confounding factors, such as diabetes mellitus or age.
Genotypes of all groups were in Hardy-Weinberg equilibrium. There were no differences when the global hypertensive group was compared with the control population (42.7 vs 40.9%; P ¼ 0.74) or when each hypertensive group (resistant or controlled) was compared individually with the control population (resistant vs control group: 57.1 vs 40.9% P ¼ 0.06; controlled vs control group: 39.7 vs 40.9% P ¼ 0.82). However, genotypic distribution did differ significantly when patients with refractory hypertension were compared with those with controlled hypertension. The GSTM1 null genotype was significantly more frequent in patients with resistant hypertension (57.1 vs 39.7%; P ¼ 0.03; RR 1.96; 95% CI 1.04-3.69).
The GST proteins are fundamental to the control of cellular stress. 9 Polymorphisms in GST genes have been associated with susceptibility to several diseases and may modulate drug response. 9 However, an association with development and maintenance of primary hypertension in humans has not been assessed. Although GSTP has been linked to hypertension during pregnancy 10 and decreased GST activity was detected in the erythrocytes of hypertensive patients. It has been suggested that GST may act as a nitric oxide carrier in some circumstances.
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Decreased GSTM1 expression in stroke-prone spontaneously hypertensive rats 10 may reduce antioxidant defences. Resulting lower renal GSTM1 levels may lead to increased superoxide formation and reduced nitric oxide bioavailability in the renal medulla and cortex. 10 Indeed, these findings parallel those in other clinical and experimental models. 12 However, the null GSTM1 genotype has not been linked to hypertension in humans.
Our results showed that individuals who lacked the GSTM1 gene had a two-fold increased risk of developing resistant hypertension when compared with those with controlled hypertension (Table 1) . These results suggest that carriage of the GSTM1 gene may protect against resistant hypertension. Our results further indicate that variable GSTM1 activity may predispose to endothelial dysfunction and development and maintenance of resistant hypertension.
We propose therefore that predisposition to the development of resistant hypertension may be determined at least in part at a genetic level. However, we acknowledge that resistant hypertension is a multifactorial syndrome that most likely reflects a composite of variation in other genes and interaction with environmental factors.
In conclusion, this study shows for the first time that the null GSTM1 genotype may be associated with refractory hypertension in humans. Functional assessment of this association is required to clarify the underlying mechanism.
